Recombinant activated factor VII in post partum haemorrhage.

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Critical Care Medicine

Background:

• Postpartum hemorrhage (PPH) is a leading cause of maternal mortality worldwide.
• Current management strategies, including invasive and surgical methods, have limitations, leading to high mortality rates.
• Advancements in treatment are crucial for improving outcomes in severe PPH.

Purpose of the Study:

• To evaluate the efficacy of recombinant activated factor VII (rFVIIa) in managing intractable postpartum hemorrhage.
• To present clinical experience with rFVIIa as a hemostatic agent in PPH cases.
• To highlight rFVIIa as a potential alternative to hysterectomy in refractory PPH.

Main Methods:

• Retrospective case series analysis of PPH patients treated with rFVIIa.
• Assessment of hemorrhage arrest based on visual evidence and hemodynamic stabilization.
• Evaluation of blood component usage and therapy costs.

Main Results:

• rFVIIa demonstrated effective control of postpartum hemorrhage in the studied cases.
• Hemodynamic stabilization and arrest of bleeding were observed as key indicators of efficacy.
• Reduced need for blood components and associated therapy costs in massive PPH were noted.

Conclusions:

• Recombinant activated factor VII is a valuable hemostatic agent for managing severe postpartum hemorrhage.
• Consideration of rFVIIa before resorting to hysterectomy in intractable PPH cases is recommended.
• rFVIIa represents a significant advancement in PPH treatment, potentially reducing maternal mortality.